Selected research
Industry Research
Sulfonylurea Hypoglycemic Drugs Industry Research Report 2026
Market perspective
The global Sulfonylurea Hypoglycemic Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Sulfonylurea Hypoglycemic Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Sulfonylurea Hypoglycemic Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Sulfonylurea Hypoglycemic Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Sulfonylurea Hypoglycemic Drugs include United Laboratories, Takeda, Sanofi, Novo Nordisk, Merck, Eli Lilly, Jiangsu Hengrui Pharmaceuticals, Pfizer and Beijing Double-Crane Pharmaceutical, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Sulfonylurea Hypoglycemic Drugs market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sulfonylurea Hypoglycemic Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sulfonylurea Hypoglycemic Drugs Market by Company
United Laboratories
Takeda
Sanofi
Novo Nordisk
Merck
Eli Lilly
Jiangsu Hengrui Pharmaceuticals
Pfizer
Beijing Double-Crane Pharmaceutical
Huadong Medicine
GSK
Beijing Beilu Pharmaceutical
AstraZeneca
Boehringer Ingelheim
Sulfonylurea Hypoglycemic Drugs Segment by Type
First Generation Sulfonylureas
Second Generation Sulfonylureas
Third Generation Sulfonylureas
Sulfonylurea Hypoglycemic Drugs Segment by Application
Pharmacy
Hospital
Clinic
Others
Sulfonylurea Hypoglycemic Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sulfonylurea Hypoglycemic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sulfonylurea Hypoglycemic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sulfonylurea Hypoglycemic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Sulfonylurea Hypoglycemic Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Generation Sulfonylureas
- Second Generation Sulfonylureas
- Third Generation Sulfonylureas
Applications
- Pharmacy
- Hospital
- Clinic
- Others
Companies covered
- United Laboratories
- Takeda
- Sanofi
- Novo Nordisk
- Merck
- Eli Lilly
- Jiangsu Hengrui Pharmaceuticals
- Pfizer
- Beijing Double-Crane Pharmaceutical
- Huadong Medicine
- GSK
- Beijing Beilu Pharmaceutical
- AstraZeneca
- Boehringer Ingelheim
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Sulfonylurea Hypoglycemic Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 First Generation Sulfonylureas
- 2.2.3 Second Generation Sulfonylureas
- 2.2.4 Third Generation Sulfonylureas
- 2.3 Sulfonylurea Hypoglycemic Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmacy
- 2.3.3 Hospital
- 2.3.4 Clinic
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Sulfonylurea Hypoglycemic Drugs Breakdown Data by Type
- 3.1 Global Sulfonylurea Hypoglycemic Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Sulfonylurea Hypoglycemic Drugs Forecasted Market Size by Type (2027-2032)
4 Sulfonylurea Hypoglycemic Drugs Breakdown Data by Application
- 4.1 Global Sulfonylurea Hypoglycemic Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Sulfonylurea Hypoglycemic Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Sulfonylurea Hypoglycemic Drugs Market Perspective (2021-2032)
- 5.2 Global Sulfonylurea Hypoglycemic Drugs Growth Trends by Region
- 5.2.1 Global Sulfonylurea Hypoglycemic Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Sulfonylurea Hypoglycemic Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Sulfonylurea Hypoglycemic Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Sulfonylurea Hypoglycemic Drugs Market Dynamics
- 5.3.1 Sulfonylurea Hypoglycemic Drugs Industry Trends
- 5.3.2 Sulfonylurea Hypoglycemic Drugs Market Drivers
- 5.3.3 Sulfonylurea Hypoglycemic Drugs Market Challenges
- 5.3.4 Sulfonylurea Hypoglycemic Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Sulfonylurea Hypoglycemic Drugs Players by Revenue
- 6.1.1 Global Top Sulfonylurea Hypoglycemic Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Sulfonylurea Hypoglycemic Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Sulfonylurea Hypoglycemic Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Sulfonylurea Hypoglycemic Drugs Head Office and Area Served
- 6.4 Global Sulfonylurea Hypoglycemic Drugs Players, Product Type & Application
- 6.5 Global Sulfonylurea Hypoglycemic Drugs Manufacturers Established Date
- 6.6 Global Sulfonylurea Hypoglycemic Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
- 7.2 North America Sulfonylurea Hypoglycemic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 7.4 North America Sulfonylurea Hypoglycemic Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
- 8.2 Europe Sulfonylurea Hypoglycemic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 8.4 Europe Sulfonylurea Hypoglycemic Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Sulfonylurea Hypoglycemic Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
- 10.2 South America Sulfonylurea Hypoglycemic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 10.4 South America Sulfonylurea Hypoglycemic Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Sulfonylurea Hypoglycemic Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 United Laboratories
- 12.1.1 United Laboratories Company Information
- 12.1.2 United Laboratories Business Overview
- 12.1.3 United Laboratories Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.1.4 United Laboratories Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.1.5 United Laboratories Recent Developments
- 12.2 Takeda
- 12.2.1 Takeda Company Information
- 12.2.2 Takeda Business Overview
- 12.2.3 Takeda Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.2.4 Takeda Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.2.5 Takeda Recent Developments
- 12.3 Sanofi
- 12.3.1 Sanofi Company Information
- 12.3.2 Sanofi Business Overview
- 12.3.3 Sanofi Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.3.4 Sanofi Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.3.5 Sanofi Recent Developments
- 12.4 Novo Nordisk
- 12.4.1 Novo Nordisk Company Information
- 12.4.2 Novo Nordisk Business Overview
- 12.4.3 Novo Nordisk Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.4.4 Novo Nordisk Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.4.5 Novo Nordisk Recent Developments
- 12.5 Merck
- 12.5.1 Merck Company Information
- 12.5.2 Merck Business Overview
- 12.5.3 Merck Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.5.4 Merck Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.5.5 Merck Recent Developments
- 12.6 Eli Lilly
- 12.6.1 Eli Lilly Company Information
- 12.6.2 Eli Lilly Business Overview
- 12.6.3 Eli Lilly Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.6.4 Eli Lilly Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.6.5 Eli Lilly Recent Developments
- 12.7 Jiangsu Hengrui Pharmaceuticals
- 12.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
- 12.7.2 Jiangsu Hengrui Pharmaceuticals Business Overview
- 12.7.3 Jiangsu Hengrui Pharmaceuticals Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.7.4 Jiangsu Hengrui Pharmaceuticals Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
- 12.8 Pfizer
- 12.8.1 Pfizer Company Information
- 12.8.2 Pfizer Business Overview
- 12.8.3 Pfizer Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.8.4 Pfizer Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.8.5 Pfizer Recent Developments
- 12.9 Beijing Double-Crane Pharmaceutical
- 12.9.1 Beijing Double-Crane Pharmaceutical Company Information
- 12.9.2 Beijing Double-Crane Pharmaceutical Business Overview
- 12.9.3 Beijing Double-Crane Pharmaceutical Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.9.4 Beijing Double-Crane Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.9.5 Beijing Double-Crane Pharmaceutical Recent Developments
- 12.10 Huadong Medicine
- 12.10.1 Huadong Medicine Company Information
- 12.10.2 Huadong Medicine Business Overview
- 12.10.3 Huadong Medicine Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.10.4 Huadong Medicine Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.10.5 Huadong Medicine Recent Developments
- 12.11 GSK
- 12.11.1 GSK Company Information
- 12.11.2 GSK Business Overview
- 12.11.3 GSK Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.11.4 GSK Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.11.5 GSK Recent Developments
- 12.12 Beijing Beilu Pharmaceutical
- 12.12.1 Beijing Beilu Pharmaceutical Company Information
- 12.12.2 Beijing Beilu Pharmaceutical Business Overview
- 12.12.3 Beijing Beilu Pharmaceutical Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.12.4 Beijing Beilu Pharmaceutical Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.12.5 Beijing Beilu Pharmaceutical Recent Developments
- 12.13 AstraZeneca
- 12.13.1 AstraZeneca Company Information
- 12.13.2 AstraZeneca Business Overview
- 12.13.3 AstraZeneca Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.13.4 AstraZeneca Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.13.5 AstraZeneca Recent Developments
- 12.14 Boehringer Ingelheim
- 12.14.1 Boehringer Ingelheim Company Information
- 12.14.2 Boehringer Ingelheim Business Overview
- 12.14.3 Boehringer Ingelheim Revenue in Sulfonylurea Hypoglycemic Drugs Business (2021-2026)
- 12.14.4 Boehringer Ingelheim Sulfonylurea Hypoglycemic Drugs Product Portfolio
- 12.14.5 Boehringer Ingelheim Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst